Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 7:12:665756.
doi: 10.3389/fimmu.2021.665756. eCollection 2021.

The Evolving Landscape of Biomarkers in Celiac Disease: Leading the Way to Clinical Development

Glennda Smithson  1 , Jenifer Siegelman  1 , Toshihiko Oki  1 , Joseph R Maxwell  1 , Daniel A Leffler  1   2
Affiliations
Review

The Evolving Landscape of Biomarkers in Celiac Disease: Leading the Way to Clinical Development

Glennda Smithson et al. Front Immunol. .

Abstract

Celiac disease is a common immune-mediated disease characterized by abnormal T-cell responses to gluten. For many patients, symptoms and intestinal damage can be controlled by a gluten-free diet, but, for some, this approach is not enough, and celiac disease progresses, with serious medical consequences. Multiple therapies are now under development, increasing the need for biomarkers that allow identification of specific patient populations and monitoring of therapeutic activity and durability. The advantage of identifying biomarkers in celiac disease is that the underlying pathways driving disease are well characterized and the histological, cellular, and serological changes with gluten response have been defined in gluten challenge studies. However, there is room for improvement. Biomarkers that measure histological changes require duodenal biopsies and are invasive. Less invasive peripheral blood cell and cytokine biomarkers are transient and dependent upon gluten challenge. Here, we discuss established biomarkers and new approaches for biomarkers that may overcome current limitations.

Keywords: biomarkers; celiac disease; clinical development; diagnosis; disease monitoring; patient populations.

PubMed Disclaimer

Conflict of interest statement

The authors declare that this study was funded by Takeda Pharmaceutical Company Ltd. All authors were employees of Takeda Pharmaceuticals Inc. Co., and were responsible for the content, collection, analysis, interpretation of data, preparation of this article and the decision to submit it for publication.

Similar articles

See all similar articles

Cited by

References

    1. Jabri B, Sollid LM. T cells in celiac disease. J Immunol (2017) 198:3005–14. 10.4049/jimmunol.1601693 - DOI - PMC - PubMed
    1. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. . Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2018) 16:823–36.e2. 10.1016/j.cgh.2017.06.037 - DOI - PubMed
    1. Leffler DA, Dennis M, Hyett B, Kelly E, Schuppan D, Kelly CP. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol (2007) 5:445–50. 10.1016/j.cgh.2006.12.006 - DOI - PubMed
    1. Leonard MM, Cureton P, Fasano A. Indications and use of the gluten contamination elimination diet for patients with non-responsive celiac disease. Nutrients (2017) 9:1129. 10.3390/nu9101129 - DOI - PMC - PubMed
    1. Food and Agriculture Organization of the United Nations . World Health Organization. Standard for foods for special dietary use for persons intolerant to gluten. Codex Stan 118-1979. Adopted in 1979. Amendment: 1983 and 2015. Revision. (2008). Available at: http://www.fao.org/fao-who-codexalimentarius/sh-proxy/en/?lnk=1&url=http...

Publication types